Vitamin C to fight Cancer.
This is information that needs to be disseminated:
Intravenous Ascorbate as a Chemotherapeutic and Biologic Response Modifying Agent
by The Center for the Improvement of Human Functioning, International, Inc., Bio-Communications Research Institute.Reprinted with permission.
(Emphasis added by DoctorYourself.com editor Andrew Saul)
Additional research papers may be read athttp://brightspot.org/cresearch/index.shtml
For over 15 years we have studied high dose intravenous ascorbic acid (IAA) as an adjunctive therapy for cancer patients. Initially, doses of 15 g per infusion were used, once or twice per week. These doses improved patient’s sense of well being, reduced pain, and in many cases prolonged life beyond prognostications of oncologists.
Twelve years ago, we used infusions of 30 grams of intravenous ascorbic acid, twice per week, and found that metastatic lesions in the lung and liver of a man with a primary renal cell carcinoma disappeared in a matter of weeks (1). At that time we believed IAA was useful for patients with cancer solely through two biological response modifier mechanisms: increased production of extracellular collagen (“walling off’ the tumor as proposed by Cameron and Pauling) and enhancement of immune function. We subsequently reported a case of resolution of bone metastases in a patient with primary breast cancer (1A) using infusions of 100 grams, once or twice per week (2).
In a recent publication (3) we presented evidence that ascorbic acid and its salts (AA) could be more than biological response modifiers. We found that ascorbic acid is preferentially toxic to tumor cells suggesting that it could be useful as a chemotherapeutic agent. Preferential toxicity occurred in vitro in multiple tumor cell types. We also presented data suggesting that plasma concentrations of ascorbate required for killing tumor cells were achievable in humans. Others have described in vivo toxicity in multiple tumor types and animal models (4-8).
Here we wish to summarize our experience using IAA for approximately 50 patients with cancer. We include our protocol, precautions, and case studies of two patients treated for metastatic renal cell carcinoma.
From our studies (3) we concluded that:
Tumor cells are more susceptible to the effects of high-dose, ascorbate-induced peroxidation products because of a relative catalase deficiency; and,
Concentrations of ascorbate high enough to kill tumor cells likely can be achieved in humans.